Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir

M van Luin, Marchina Ende, C Richter, Martje Visser, D Faraj, A van de Ven, Luc Gelinck, F Kroon, FW Wit, Ron van Schaik, PFM Kuks, DM Burger

Research output: Contribution to journalArticleAcademicpeer-review

37 Citations (Scopus)


HIV-infected travellers frequently use atovaquone/ proguanil as malaria prophylaxis. We compared atovaquone/ proguanil pharmacokinetics between healthy volunteers and HIV-infected patients taking efavirenz, lopinavir/ ritonavir or atazanavir/ritonavir. The geometric mean ratio (95% confidence interval) area under the curve (AUC)(0 -> t) for atovaquone relative to the healthy volunteers was 0.25 (0.16-0.38), 0.26 (0.17-0.41) and 0.54 (0.350.83) for patients on efavirenz, lopinavir/ ritonavir and atazanavir/ ritonavir, respectively. Proguanil plasma concentrations were also significantly lower (38-43%). Physicians should be alert for atovaquone/ proguanil prophylaxis failures in patients taking efavirenz, lopinavir/ ritonavir or atazanavir/ ritonavir.
Original languageUndefined/Unknown
Pages (from-to)1223-1226
Number of pages4
Issue number8
Publication statusPublished - 2010

Research programs

  • EMC MM-01-25-01
  • EMC MM-04-28-04

Cite this